Novel	O
biomarkers	B:C0041366
in	O
primary	O
breast	B:C0191853
core	I:C0191853
biopsies	I:C0191853
to	O
predict	O
poor	B:C1320680
response	I:C1320680
to	O
neoadjuvant	O
chemotherapy	O
and	O
appearance	O
of	O
metastases	B:C0027627
.	O

Drug	B:C0013203
resistance	I:C0013203
has	O
been	O
one	O
of	O
the	O
major	O
obstacles	O
limiting	O
the	O
success	O
of	O
cancer	B:C0006826
chemotherapy	B:C3665472
.	O

In	O
two	O
thirds	O
of	O
breast	B:C0006142
cancer	I:C0006142
patients	O
,	O
large	O
(	O
>	O
1	O
cm	O
)	O
residual	B:C0543478
tumors	I:C0543478
are	O
present	O
after	O
neoadjuvant	O
chemotherapy	O
(	O
NCT	O
)	O
.	O

The	O
residual	B:C0543478
tumor	I:C0543478
and	O
involved	O
nodes	B:C0746922
have	O
been	O
indicators	B:C0021212
of	O
relapse	O
and	O
survival	O
very	O
important	O
in	O
breast	B:C0006142
cancer	I:C0006142
.	O

The	O
goal	O
of	O
this	O
preliminary	O
study	O
was	O
to	O
assess	O
the	O
predictive	O
significance	O
of	O
a	O
panel	O
of	O
molecular	B:C0041366
biomarkers	I:C0041366
,	O
related	O
with	O
the	O
response	B:C0521982
to	I:C0521982
treatment	I:C0521982
or	O
drug	B:C0013203
resistance	I:C0013203
to	O
NCT	O
,	O
as	O
determined	O
on	O
the	O
diagnostic	O
tumor	B:C0027651
.	O

The	O
expression	B:C1171362
of	O
22	O
proteins	B:C0033684
was	O
examined	O
using	O
immunohistochemistry	B:C0021044
in	O
tissue	O
microarrays	O
(	O
TMA	O
)	O
from	O
115	O
patients	O
of	O
stage	B:C0278486
II	I:C0278486
-	O
III	B:C0278487
breast	I:C0278487
cancer	I:C0278487
,	O
treated	O
with	O
NCT	O
.	O

Among	O
studied	O
proteins	B:C0033684
,	O
there	O
are	O
some	O
that	O
are	O
anti-apoptotic	B:C0574031
,	O
pro-proliferative	B:C0574031
,	O
cancer	B:C0574031
stem	I:C0574031
cell	I:C0574031
markers	I:C0574031
and	O
the	O
Vitamin	B:C0108082
D	I:C0108082
Receptor	I:C0108082
.	O

Other	O
proteins	B:C0033684
are	O
involved	O
in	O
the	O
identification	O
of	O
molecular	B:C0449560
subtype	I:C0449560
,	O
cell	B:C1155872
cycle	I:C1155872
regulation	I:C1155872
or	O
DNA	B:C0012899
repair	I:C0012899
.	O

Next	O
,	O
a	O
predictive	O
signature	O
of	O
poor	O
response	B:C1148560
was	O
generated	O
from	O
independent	O
markers	B:C0041366
of	O
predictive	O
value	O
.	O

Tumors	B:C0027651
that	O
expressed	O
four	O
or	O
five	O
conditions	O
(	O
biomarkers	B:C0041366
of	O
chemoresistance	O
with	O
a	O
determinated	O
cutoff	O
)	O
were	O
associated	O
with	O
a	O
9	O
-	O
fold	O
increase	O
in	O
the	O
chances	O
of	O
these	O
patients	O
of	O
having	O
a	O
poor	B:C1320680
response	I:C1320680
to	O
NCT	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
a	O
worse	O
prognostic	O
signature	O
,	O
generated	O
from	O
independent	O
markers	B:C0041366
of	O
prognostic	O
value	O
.	O

Tumors	B:C0027651
which	O
expressed	O
two	O
or	O
three	O
conditions	O
of	O
worst	O
prognostic	O
,	O
were	O
associated	O
with	O
a	O
6	O
-	O
fold	O
reduction	O
in	O
Distant	O
Disease	O
Free	O
Survival	O
.	O

In	O
conclusion	O
,	O
finding	B:C0243095
biomarkers	B:C0041366
of	O
chemoresitance	O
(	O
ypTNM	B:C0008902
II	I:C0008902
-	I:C0008902
III	I:C0008902
)	O
and	O
metastases	B:C0027627
can	O
become	O
a	O
stepping	O
stone	O
for	O
future	O
studies	O
that	O
will	O
need	O
to	O
be	O
assessed	O
in	O
a	O
bigger	O
scale	O
.	O

